peficitinib: Clinical Trials

4 trials of peficitinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4

Follow peficitinib: new trials by email Literature Review of peficitinib trials Research Report on peficitinib

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs) - Rheumatoid Arthritis (RA)
Phase 3CompletedAstellas Pharma China, Inc.3852018-09-272024-10-21
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
Peficitinib, Placebo, Etanercept - Rheumatoid Arthritis
Phase 3CompletedAstellas Pharma Inc5092014-08-082024-10-28
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment
Peficitinib, Placebo, Methotrexate - Rheumatoid Arthritis
Phase 3CompletedAstellas Pharma Inc5192014-07-252024-10-28
A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K
Peficitinib - Arthritis, Rheumatoid
Phase 3CompletedAstellas Pharma Inc8432012-06-132024-10-28

Conditions studied

Arthritis, Rheumatoid (4)

Sponsors

Astellas Pharma Inc (3)  ·  Astellas Pharma China, Inc. (1)

Countries

Japan (3)  ·  South Korea (3)  ·  Taiwan (3)  ·  China (1)

Results publications

PMID 33068028, PMID 33929089, PMID 34429152, PMID 31350269, PMID 31350270, PMID 32164762, PMID 33656739, PMID 35267027, PMID 38357391